Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response

Neuron

Volumn 99, Issue 5, 2018, Pages 914-924.e3

  Syed, Shariful A ^a   Beurel, Eléonore ^a   Loewenstein, David A ^a   Lowell, Jeffrey A ^a   Craighead, W Edward ^b,c   Dunlop, Boadie W ^b   Mayberg, Helen S ^b   Dhabhar, Firdaus ^a   Dietrich, W Dalton ^a   Keane, Robert W ^a   de Rivero Vaccari, Juan Pablo ^a   Nemeroff, Charles B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

cytokines; defective anti inflammatory pathway; inflammasome; major depressive disorder; PBMC; T cell memory; treatment naive

Indexed keywords

CYTOKINE; INFLAMMASOME; AUTACOID; BIOLOGICAL MARKER;

ADULT; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSYCHOTHERAPY; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; BLOOD; MAJOR DEPRESSION; MIDDLE AGED; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; BIOMARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85056458403     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2018.08.001     Document Type: Article

References (54)

1. Alcocer-Gómez, E., de Miguel, M., Casas-Barquero, N., Núñez-Vasco, J., Sánchez-Alcazar, J.A., Fernández-Rodríguez, A., Cordero, M.D., NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 36 (2014), 111–117.
2. Beck, A.T., Cognitive Therapy of Depression. 1979, Guilford press.
3. Brand, F.J. 3rd, Forouzandeh, M., Kaur, H., Travascio, F., de Rivero Vaccari, J.P., Acidification changes affect the inflammasome in human nucleus pulposus cells. J. Inflamm. (Lond.), 13, 2016, 29.
4. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
5. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
6. Dunlop, B.W., Binder, E.B., Cubells, J.F., Goodman, M.M., Kelley, M.E., Kinkead, B., Kutner, M., Nemeroff, C.B., Newport, D.J., Owens, M.J., et al. Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials, 13, 2012, 106.
7. Dunlop, B.W., Kelley, M.E., Aponte-Rivera, V., Mletzko-Crowe, T., Kinkead, B., Ritchie, J.C., Nemeroff, C.B., Craighead, W.E., Mayberg, H.S., PReDICT Team. Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. Am. J. Psychiatry 174 (2017), 546–556.
8. Dunlop, B.W., Rajendra, J.K., Craighead, W.E., Kelley, M.E., McGrath, C.L., Choi, K.S., Kinkead, B., Nemeroff, C.B., Mayberg, H.S., Functional connectivity of the subcallosal cingulate cortex and differential outcomes to treatment with cognitive-behavioral therapy or antidepressant medication for major depressive disorder. Am. J. Psychiatry 174 (2017), 533–545.
9. Fantuzzi, G., Dinarello, C.A., Interleukin-18 and interleukin-1 β: two cytokine substrates for ICE (caspase-1). J. Clin. Immunol. 19 (1999), 1–11.
10. Frampton, J.E., Plosker, G.L., Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 21 (2007), 581–609.
11. Glassman, A.H., O'Connor, C.M., Califf, R.M., Swedberg, K., Schwartz, P., Bigger, J.T. Jr., Krishnan, K.R., van Zyl, L.T., Swenson, J.R., Finkel, M.S., et al., Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288 (2002), 701–709.
12. Greeson, J.M., Gettes, D.R., Spitsin, S., Dubé, B., Benton, T.D., Lynch, K.G., Douglas, S.D., Evans, D.L., The selective serotonin reuptake inhibitor citalopram decreases human immunodeficiency virus receptor and coreceptor expression in immune cells. Biol. Psychiatry 80 (2016), 33–39.
13. Grosse, L., Carvalho, L.A., Birkenhager, T.K., Hoogendijk, W.J., Kushner, S.A., Drexhage, H.A., Bergink, V., Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology (Berl.) 233 (2016), 1679–1688.
14. Guo, H., Callaway, J.B., Ting, J.P.Y., Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21 (2015), 677–687.
15. Hamilton, M., A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960), 56–62.
16. Hofmann, S.G., Asnaani, A., Vonk, I.J.J., Sawyer, A.T., Fang, A., The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit. Ther. Res. 36 (2012), 427–440.
17. Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71 (2009), 171–186.
18. Kappelmann, N., Lewis, G., Dantzer, R., Jones, P.B., Khandaker, G.M., Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry 23 (2018), 335–343.
19. Kenis, G., Maes, M., Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5 (2002), 401–412.
20. Kessler, D., Sharp, D., Lewis, G., Screening for depression in primary care. Br. J. Gen. Pract. 55 (2005), 659–660.
21. Kiraly, D.D., Horn, S.R., Van Dam, N.T., Costi, S., Schwartz, J., Kim-Schulze, S., Patel, M., Hodes, G.E., Russo, S.J., Merad, M., et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl. Psychiatry, 7, 2017, e1065.
22. Köhler, O., Benros, M.E., Nordentoft, M., Farkouh, M.E., Iyengar, R.L., Mors, O., Krogh, J., Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71 (2014), 1381–1391.
23. Köhler, C.A., Freitas, T.H., Maes, M., de Andrade, N.Q., Liu, C.S., Fernandes, B.S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand. 135 (2017), 373–387.
24. Kubera, M., Maes, M., Holan, V., Basta-Kaim, A., Roman, A., Shani, J., Prolonged desipramine treatment increases the production of interleukin-10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression. J. Affect. Disord. 63 (2001), 171–178.
25. Langley, R.G., Feldman, S.R., Han, C., Schenkel, B., Szapary, P., Hsu, M.-C., Ortonne, J.-P., Gordon, K.B., Kimball, A.B., Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J. Am. Acad. Dermatol. 63 (2010), 457–465.
26. Lanquillon, S., Krieg, J.C., Bening-Abu-Shach, U., Vedder, H., Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22 (2000), 370–379.
27. Liu, Y., Ho, R.C.-M., Mak, A., Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord. 139 (2012), 230–239.
28. Loftus, E.V., Feagan, B.G., Colombel, J.-F., Rubin, D.T., Wu, E.Q., Yu, A.P., Pollack, P.F., Chao, J., Mulani, P., Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol. 103 (2008), 3132–3141.
29. Maes, M., Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995), 11–38.
30. Maes, M., Song, C., Lin, A.-H., Bonaccorso, S., Kenis, G., De Jongh, R., Bosmans, E., Scharpé, S., Negative immunoregulatory effects of antidepressants: inhibition of interferon-γ and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20 (1999), 370–379.
31. Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., Maj, M., The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 24 (2009), 27–53.
32. Marshall, J.D., Aste-Amézaga, M., Chehimi, S.S., Murphy, M., Olsen, H., Trinchieri, G., Regulation of human IL-18 mRNA expression. Clin. Immunol. 90 (1999), 15–21.
33. Martinon, F., Burns, K., Tschopp, J., The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10 (2002), 417–426.
34. McKay, M.S., Zakzanis, K.K., The impact of treatment on HPA axis activity in unipolar major depression. J. Psychiatr. Res. 44 (2010), 183–192.
35. Menter, A., Augustin, M., Signorovitch, J., Yu, A.P., Wu, E.Q., Gupta, S.R., Bao, Y., Mulani, P., The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J. Am. Acad. Dermatol. 62 (2010), 812–818.
36. Miller, A.H., Raison, C.L., Are anti-inflammatory therapies viable treatments for psychiatric disorders?: where the rubber meets the road. JAMA Psychiatry 72 (2015), 527–528.
37. Miller, A.H., Raison, C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16 (2016), 22–34.
38. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65 (2009), 732–741.
39. Mocellin, S., Panelli, M.C., Wang, E., Nagorsen, D., Marincola, F.M., The dual role of IL-10. Trends Immunol. 24 (2003), 36–43.
40. Otte, C., Gold, S.M., Penninx, B.W., Pariante, C.M., Etkin, A., Fava, M., Mohr, D.C., Schatzberg, A.F., Major depressive disorder. Nat. Rev. Dis. Primers, 2, 2016, 16065.
41. Puren, A.J., Fantuzzi, G., Gu, Y., Su, M.S., Dinarello, C.A., Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J. Clin. Invest. 101 (1998), 711–721.
42. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41.
43. Sancho, D., Gómez, M., Sánchez-Madrid, F., CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26 (2005), 136–140.
44. Schmidt, H.D., Shelton, R.C., Duman, R.S., Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36 (2011), 2375–2394.
45. Sen, S., Duman, R., Sanacora, G., Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64 (2008), 527–532.
46. Shinoda, K., Tokoyoda, K., Hanazawa, A., Hayashizaki, K., Zehentmeier, S., Hosokawa, H., Iwamura, C., Koseki, H., Tumes, D.J., Radbruch, A., Nakayama, T., Type II membrane protein CD69 regulates the formation of resting T-helper memory. Proc. Natl. Acad. Sci. USA 109 (2012), 7409–7414.
47. Simpson, E., Worm, M., Soong, W., Blauvelt, A., Eckert, L., Wu, R., Ardeleanu, M., Graham, N., Pirozzi, G., Sutherland, E.R., Dupilumab improves patient-reported outcomes (PROs) in a Phase 2 study in adults with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol., 135, 2015, AB167.
48. Sluzewska, A., Sobieska, M., Rybakowski, J.K., Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 35 (1997), 123–127.
49. Subauste, C.S., de Waal Malefyt, R., Fuh, F., Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen. J. Immunol. 160 (1998), 1831–1840.
50. Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006), 29–35.
51. Tyring, S., Bagel, J., Lynde, C., Klekotka, P., Thompson, E.H.Z., Gandra, S.R., Shi, Y., Kricorian, G., Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept. J. Eur. Acad. Dermatol. Venereol. 27 (2013), 125–128.
52. Warner-Schmidt, J.L., Vanover, K.E., Chen, E.Y., Marshall, J.J., Greengard, P., Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc. Natl. Acad. Sci. USA 108 (2011), 9262–9267.
53. Wieland, E., Shipkova, M., Lymphocyte surface molecules as immune activation biomarkers. Clin. Biochem. 49 (2016), 347–354.
54. Zhu, J., Yamane, H., Paul, W.E., Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28 (2010), 445–489.